iOmx Therapeutics raises EUR 65 million in Series B round6. October 2021|In Portfolio News|By eazee-designstudioiOmx Therapeutics AG (iOmx), a biopharmaceutical company developing cancer therapeutics based on next generation immune checkpoint targets, today announced the closing of a Series B round totaling EUR 65 million. PrevNext
